WEBULL
News
BIOYF
9.23
+2.10%
0.19
These Healthcare Stocks Just Exploded In Momentum — Investors Are Taking Notice
Benzinga · 12/03 20:57
BioSyent declares CAD 0.05 dividend
Seeking Alpha · 11/21 11:16
BioSyent  GAAP EPS of C$0.23, revenue of C$12.22M
Seeking Alpha · 11/20 22:35
BioSyent Declares Fourth Quarter 2025 Dividend
Barchart · 11/20 16:29
Beyond the S&P 500: Finding Overlooked Opportunities in Small Caps
Barchart · 09/30 10:53
Weekly Report: what happened at BIOYF last week (0908-0912)?
Weekly Report · 09/15 10:08
Weekly Report: what happened at BIOYF last week (0901-0905)?
Weekly Report · 09/08 10:09
Weekly Report: what happened at BIOYF last week (0825-0829)?
Weekly Report · 09/01 10:07
Weekly Report: what happened at BIOYF last week (0818-0822)?
Weekly Report · 08/25 10:12
BioSyent declares CAD 0.05 dividend
Seeking Alpha · 08/22 04:49
BioSyent Declares Third Quarter 2025 Dividend
Barchart · 08/21 15:43
Weekly Report: what happened at BIOYF last week (0811-0815)?
Weekly Report · 08/18 10:08
BioSyent Schedules Q2 and H1 2025 Earnings Release for August 21, 2025
Barchart · 08/14 16:00
Weekly Report: what happened at BIOYF last week (0804-0808)?
Weekly Report · 08/11 10:11
Weekly Report: what happened at BIOYF last week (0728-0801)?
Weekly Report · 08/04 10:13
Weekly Report: what happened at BIOYF last week (0721-0725)?
Weekly Report · 07/28 10:14
Weekly Report: what happened at BIOYF last week (0714-0718)?
Weekly Report · 07/21 10:08
Weekly Report: what happened at BIOYF last week (0707-0711)?
Weekly Report · 07/14 10:13
Weekly Report: what happened at BIOYF last week (0630-0704)?
Weekly Report · 07/07 10:09
Weekly Report: what happened at BIOYF last week (0623-0627)?
Weekly Report · 06/30 10:12
More
Webull provides a variety of real-time BIOYF stock news. You can receive the latest news about Biosyent through multiple platforms. This information may help you make smarter investment decisions.
About BIOYF
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.